Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Cash $ 3,810,139   $ 3,810,139   $ 3,027,033
Depreciation expense 21,931 $ 4,256 $ 42,509 $ 5,469  
Useful Life of patents and other technologies     5 years    
Impairment loss     $ 0 0 (1,321,338)
Intangible assets acquired         1,583,260
Due to related parties 250,000   250,000   450,000
Deferred rental income 3,525   3,525   $ 12,769
Shipping and Handling Costs 0 0 25 0  
Research and Development 1,384 0 1,647 0  
Advertising and Marketing Costs 150,548 0 $ 150,548 0  
Reverse split ratio     1:4    
Beijing GenExosome | Dr. Yu Zhou          
Equity interests ownership percentage         40.00%
Real property operating [Member]          
Depreciation expense 31,805 $ 20,066 $ 95,416 $ 53,009  
PRC [Member]          
Cash 1,654,815   1,654,815   $ 1,327,009
United States [Member]          
Cash $ 2,155,324   $ 2,155,324   $ 1,700,024